Review,
Navigating the Critical Translational Questions for Implementing FLASH in the Clinic
Affiliations
- [1] Stanford Cancer Institute [NORA names: United States; America, North; OECD];
- [2] Stanford University School of Medicine [NORA names: United States; America, North; OECD];
- [3] University of Pennsylvania [NORA names: United States; America, North; OECD];
- [4] Aarhus University Hospital [NORA names: Central Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD];
- [5] University of Cincinnati College of Medicine [NORA names: United States; America, North; OECD];
(... more)
Abstract
The “FLASH effect” is an increased therapeutic index, that is, reduced normal tissue toxicity for a given degree of anti-cancer efficacy, produced by ultra-rapid irradiation delivered on time scales orders of magnitude shorter than currently conventional in the clinic for the same doses. This phenomenon has been observed in numerous preclinical in vivo tumor and normal tissue models. While the underlying biological mechanism(s) remain to be elucidated, a path to clinical implementation of FLASH can be paved by addressing several critical translational questions. Technological questions pertinent to each beam type (eg, electron, proton, photon) also dictate the logical progression of experimentation required to move forward in safe and decisive clinical trials. Here we review the available preclinical data pertaining to these questions and how they may inform strategies for FLASH cancer therapy clinical trials.
